ABMC Announces Election of New Board Member Anthony G. Costantino, Ph.D.; Reports Results of Voting at Annual Meeting of Shareholders.

KINDERHOOK, N.Y. -- American Bio Medica Corporation (NASDAQ:ABMC) announced today that Anthony G. Costantino, Ph.D., was elected to the Board of Directors. Dr. Costantino is a forensic toxicologist who is currently Vice President of Laboratory Operations for National Medical Services, Inc. Dr. Costantino received his Ph.D., in Forensic Toxicology from the University of Maryland, School of Medicine in 1991, his M.S. in Pharmacology/Toxicology, from Duquesne University in 1984 and his B.S. in Pharmacy from Duquesne University in 1983. Dr. Costantino sits on the Board of Directors of the Society of Forensic Toxicology. He has authored and co-authored a number of publications, abstracts and presentations in the clinical chemistry and toxicology fields from 1986 through the present.

"We are pleased to have someone of Tony's caliber join our Board," stated ABMC President Edmund Jaskiewicz. "Tony's reputation in the field of toxicology, his business experience and his knowledge of our technology will be a great asset to both our research and development staff and our shareholders."

The Company also announced the results of issues brought to a vote at the Company's annual meeting of shareholders held on Tuesday, June 15, 2004.

Shareholders overwhelmingly elected the five nominees to the Company's Board of Directors. Stan Cipkowski, Edmund Jaskiewicz, Richard P. Koskey, Daniel W. Kollin and Anthony G. Costantino, Ph.D. each received over 97% of the votes cast at the meeting. The addition of Dr. Costantino brings the total number of independent directors to 3, or a majority of the Board There were no other matters brought to a vote.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid Tec(R) and Rapid Tec Cup(TM) products test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC has been named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing technology companies in North America.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2003, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.